- Home
- RCKT vs AKRO Comparison
RCKT vs AKRO Comparison
Compare RCKT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- AKRO
- Stock Information
- Founded
- RCKT 1999
- AKRO 2017
- Country
- RCKT United States
- AKRO United States
- Employees
- RCKT N/A
- AKRO N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- AKRO Health Care
- Exchange
- RCKT Nasdaq
- AKRO Nasdaq
- Market Cap
- RCKT 326.4M
- AKRO 3.9B
- IPO Year
- RCKT N/A
- AKRO 2019
- Fundamental
- Price
- RCKT $2.95
- AKRO $51.77
- Analyst Decision
- RCKT Buy
- AKRO Strong Buy
- Analyst Count
- RCKT 13
- AKRO 6
- Target Price
- RCKT $18.50
- AKRO $82.50
- AVG Volume (30 Days)
- RCKT 4.3M
- AKRO 1.7M
- Earning Date
- RCKT 08-04-2025
- AKRO 08-08-2025
- Dividend Yield
- RCKT N/A
- AKRO N/A
- EPS Growth
- RCKT N/A
- AKRO N/A
- EPS
- RCKT N/A
- AKRO N/A
- Revenue
- RCKT N/A
- AKRO N/A
- Revenue This Year
- RCKT N/A
- AKRO N/A
- Revenue Next Year
- RCKT N/A
- AKRO N/A
- P/E Ratio
- RCKT N/A
- AKRO N/A
- Revenue Growth
- RCKT N/A
- AKRO N/A
- 52 Week Low
- RCKT $2.19
- AKRO $21.02
- 52 Week High
- RCKT $26.98
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- RCKT 41.69
- AKRO 49.14
- Support Level
- RCKT $2.40
- AKRO $51.08
- Resistance Level
- RCKT $2.70
- AKRO $57.35
- Average True Range (ATR)
- RCKT 0.21
- AKRO 2.21
- MACD
- RCKT 0.15
- AKRO -0.81
- Stochastic Oscillator
- RCKT 73.53
- AKRO 11.08
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.